Vasogen to Conduct Webcast and Conference Call of Annual Meeting



    MISSISSAUGA, ON, March 28 /CNW/ - Vasogen Inc. (NASDAQ:  VSGN; TSX:VAS), a
biotechnology Company focused on the research and commercial development of
technologies targeting the chronic inflammation underlying cardiovascular and
neurological disease, will conduct a live webcast presentation and conference
call of its Annual and Special Meeting of Shareholders being held at the MaRS
Discovery District, Toronto, on Tuesday, April 3, 2007, at 4:30 p.m. ET
(Toronto Time).

    
    To participate via webcast, please go to www.vasogen.com.

    To participate by telephone, please connect 10 minutes prior to the call
    to one of the following:

                 -------------------------------------------
                  Direct Dial:  416-644-3419
                 -------------------------------------------
                  Toll-free:    1-800-814-4861
                 -------------------------------------------

    Telephone participants can also log onto www.vasogen.com to follow the
    slide presentation and will have the opportunity to ask questions.

    A re-broadcast of the conference call will be available at
    www.vasogen.com and may also be accessed by:

                 -------------------------------------------
                  Direct Dial:  416-640-1917
                 -------------------------------------------
                  Toll-free:    1-877-289-8525
                 -------------------------------------------
                  Pin code:     21224833
                                followed by the number sign
                 -------------------------------------------
    

    About Vasogen:

    Vasogen is a biotechnology company engaged in the research and
development of therapies that target the damaging inflammation associated with
cardiovascular and neurodegenerative disorders. The Company's lead product,
the Celacade(TM) technology, is designed to trigger the immune response to
apoptosis - an important physiological process that regulates inflammation.
Celacade(TM) is in late-stage development for the treatment of chronic heart
failure. The Company is also developing VP025, an early-stage new drug
candidate for the treatment of certain neurodegenerative diseases.

    Certain statements contained in this press release, the upcoming
conference call and web cast, or elsewhere in our public documents constitute
"forward-looking statements" within the meaning of the United States Private
Securities Litigation Reform Act of 1995 and/or "forward-looking information"
under the Securities Act (Ontario). These statements may include, without
limitation, summary statements relating to results of the ACCLAIM trial in
patients with chronic heart failure, plans to advance the development of
Celacade(TM), plans to fund our current activities, statements concerning our
partnering activities and health regulatory submissions, strategy, future
operations, future financial position, future revenues, projected costs,
prospects, plans and objectives of management. In some cases, you can identify
forward-looking statements by terminology such as "may", "will", "should",
"expects", "plans", "anticipates", "believes", "estimated", "predicts",
"potential", "continue", "intends", "could", or the negative of such terms or
other comparable terminology. We made a number of assumptions in the
preparation of these forward-looking statements, including assumptions about
the nature, size and accessibility of the market for Celacade in the treatment
of chronic heart failure, particularly in Europe, the regulatory approval
process leading to commercialization and the availability of capital on
acceptable terms to pursue the development of Celacade, and the feasibility of
additional trials. You should not place undue reliance on our forward-looking
statements which are subject to a multitude of risks and uncertainties that
could cause actual results, future circumstances or events to differ
materially from those projected in the forward-looking statements. These risks
include, but are not limited to, the outcome of further analysis of the
ACCLAIM trial results, the requirement or election to conduct additional
clinical trials, delays or setbacks in the regulatory approval process,
securing and maintaining corporate alliances, the need for additional capital
and the effect of capital market conditions and other factors on capital
availability, the potential dilutive effects of any financing, risks
associated with the outcome of our research and development programs, the
adequacy, timing and results of our clinical trials, competition, market
acceptance of our products, the availability of government and insurance
reimbursements for our products, the strength of intellectual property,
reliance on subcontractors and key personnel, losses due to fluctuations in
the U.S.-Canadian exchange rate, and other risks detailed from time to time in
our public disclosure documents or other filings with the Canadian and U.S.
securities commissions or other securities regulatory bodies. Additional risks
and uncertainties relating to our Company and our business can be found in the
"Risk Factors" section of our Annual Information Form and Form 20-F for the
year ended November 30, 2006, as well as in our later public filings. The
forward-looking statements are made as of the date hereof, and we disclaim any
intention and have no obligation or responsibility, except as required by law,
to update or revise any forward-looking statements, whether as a result of new
information, future events or otherwise. Unless otherwise indicated, numerical
values indicating the statistical significance ("p-values") of results
included in this document are based on analyses that do not account for
endpoint multiplicity.

    %SEDAR: 00001047E          %CIK: 0001042018




For further information:

For further information: Glenn Neumann, Investor Relations, 2505
Meadowvale Blvd., Mississauga, ON, Canada, L5N 5S2, tel: (905) 817-2004, fax:
(905) 569-9231, www.vasogen.com, investor@vasogen.com

Organization Profile

VASOGEN INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890